Fetal Hb Gene Induction for Sickle Cell &b-thalassemia

Period of Performance: 02/01/1996 - 01/31/1997

Unknown

Phase 2 SBIR

Recipient Firm

OSI Pharmaceuticals, Inc.
Uniondale, NY 11553
Principal Investigator